Gossamer Bio Inc. (GOSS) Announces $212M Private Placement Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Evercore ISI Downgrades Gossamer Bio Inc. (GOSS) to In Line, 'Long Path Ahead'
July 20, 2023 11:37 AM EDTEvercore ISI analyst Josh Schimmer downgraded Gossamer Bio Inc. (NASDAQ: GOSS) from Outperform to In Line with a price target of $4.00 (from $6.00).
The analyst comments "GOSS reported an initial look at the P2 OLE data for seralutinib in PAH, along with a large financing... More
